Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials

Authors: Paul E. Sax, David A. Wohl, Michael T. Yin, Frank A. Post, Edwin DeJesus, Michael S. Saag, Anton Pozniak, Melanie Thompson, Daniel Podzamczer, Jean‐Michel Molina, Shinichi Oka, Ellen Koenig, Benoît Trottier, Jaime Andrade‐Villanueva, Gordon Crofoot, Joseph M. Custodio, Andrew Plummer, Lijie Zhong, Huyen Cao, Hal Martin, Christian Callebaut, Andrew Cheng, Marshall W. Fordyce, Scott McCallister - The Lancet 2015 cited by 598